株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

急性リンパ性白血病 (ALL - リンパ芽球性白血病):パイプライン製品の分析

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 251583
出版日 ページ情報 英文 786 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.66円で換算しております。
Back to Top
急性リンパ性白血病 (ALL - リンパ芽球性白血病):パイプライン製品の分析 Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2017
出版日: 2017年05月30日 ページ情報: 英文 786 Pages
概要

急性リンパ性白血病(ALL)は、未熟なリンパ球が多数生成されることによって通常の血球の産生が妨げられている白血球の癌で、血液や、脾臓やリンパ節および肝臓などの体の他の部分にも急速に入ってきます。危険因子として、放射線や化学薬品への曝露、年齢、ウイルス感染、遺伝要因などが挙げられます。徴候は、貧血、頻繁な感染症、あざができやすくなる、骨の痛み、呼吸疾患などがあります。治療には、化学療法、輸血、移植、薬物療法が用いられます。

当レポートでは、急性リンパ性白血病(ALL:リンパ芽球性白血病)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

急性リンパ性白血病 (ALL - リンパ芽球性白血病)の概要

治療薬の開発

治療薬の評価

治療薬開発に従事している企業

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9373IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2017, provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline landscape.

Acute lymphocytic leukemia (ALL) is the cancer of the white blood cells due to the production of a large number of immature lymphocytes thus blocking the production of normal blood cells. It enters the blood stream and rapidly progress to other parts of the body such as spleen, lymph nodes and liver. Risk factors for ALL include exposure to radiation or chemicals, age, virus infections and genetic factors. Symptoms include anemia, frequent infections, easy bruising, bone pain and breathing problems. Treatment includes chemotherapy, transfusions, transplant and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 1, 3, 46, 53, 69 and 4 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 8, 12, 18 and 2 molecules, respectively.

Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Development
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics Assessment
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Drug Profiles
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..3), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..4), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..5), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..6), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..7), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..8), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..9), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..3), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..4), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..5), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by 4SC AG, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by AbbVie Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Actinium Pharmaceuticals Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ADC Therapeutics Sarl, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Aeglea BioTherapeutics Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Affimed GmbH, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Altor BioScience Corp, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Amgen Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ARA Healthcare Pvt Ltd, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ariad Pharmaceuticals Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Array BioPharma Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Atara Biotherapeutics Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bellicum Pharmaceuticals Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bexion Pharmaceuticals LLC, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bio-Path Holdings Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by BioSight Ltd, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Boehringer Ingelheim GmbH, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Calithera Biosciences Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by CanBas Co Ltd, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cantargia AB, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Celgene Corp, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellectar Biosciences Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellectis SA, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cellular Biomedicine Group Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Ceronco Biosciences, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cielo Therapeutics Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Constellation Pharmaceuticals Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Deciphera Pharmaceuticals LLC, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Eli Lilly and Company, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by EpiZyme Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Erytech Pharma SA, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Fate Therapeutics Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Formula Pharmaceuticals Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Gamida Cell Ltd, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Gilead Sciences Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Humorigin Biotechnology Corp, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by iDD biotech SAS, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Immunomedics Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Incyte Corp, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Interprotein Corp, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Jasco Pharmaceuticals LLC, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Jazz Pharmaceuticals Plc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Johnson & Johnson, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Juno Therapeutics Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Karyopharm Therapeutics Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Kiadis Pharma NV, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Kite Pharma Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Les Laboratoires Servier SAS, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by medac GmbH, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Medivir AB, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Merck & Co Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Mesoblast Ltd, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NantKwest Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NBE-Therapeutics AG, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Nimbus Therapeutics LLC, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Novartis AG, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NovImmune SA, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by NuCana BioMed Ltd, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Omeros Corp, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by OncoTartis Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by OncoTherapy Science Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Oncternal Therapeutics Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Oribase Pharma, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by OSE Immunotherapeutics, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pfenex Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pfizer Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Pharma Mar SA, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Polyphor Ltd, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sanofi, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sareum Holdings Plc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Seattle Genetics Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Shire Plc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sorrento Therapeutics Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Spectrum Pharmaceuticals Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by SYNIMMUNE GmbH, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Syros Pharmaceuticals Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Takara Bio Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Targazyme Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Threshold Pharmaceuticals Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Tolero Pharmaceuticals Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by TRACON Pharmaceuticals Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Tragara Pharmaceuticals Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Trillium Therapeutics Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Verastem Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by VioQuest Pharmaceuticals Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by Xbrane Biopharma AB, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline by ZIOPHARM Oncology Inc, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects, H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top